NASDAQ · Medical - Instruments & Supplies

Nephros, Inc. (NEPH) Stock

$3.53 +7.29% NASDAQ: NEPH Healthcare

Valuation

MetricValue
Price$3.53
Market Cap$38.32M
P/E Ratio22.84
P/B Ratio3.33
P/S Ratio1.92
EPS (TTM)$0.11
52-Week High$6.42
52-Week Low$2.66
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE16.20%
ROA11.01%
ROCE13.21%
Gross Margin5.26%
Operating Margin5.26%
Net Margin8.38%
Debt/Equity0.07
Current Ratio3.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$10.0M$10.0M$14.0M$14.0M$19.0M
Operating Profit$-3.0M$-4.0M$-2.0M$0$1.0M
Net Profit$-4.0M$-7.0M$-2.0M$0$1.0M
EPS$-0.41$-0.72$-0.15$0.01$0.11
Op Margin-31.8%-43.5%-11.2%0.0%6.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$18.0M$11.0M$12.0M$11.0M$14.0M
Total Liabilities$3.0M$2.0M$4.0M$3.0M$3.0M
Cash$7.0M$4.0M$4.0M$4.0M$5.0M
Borrowings$1.0M$1.0M$2.0M$1.0M$1.0M

Latest News

Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET GlobeNewswire · Jul 20, 2026 Northland Securities Initiates Coverage on Nephros With Market Perform Rating, $4 Price Target MT Newswires · Jul 17, 2026 Nephros Announces Inclusion in the Russell Microcap® Index GlobeNewswire · Jul 6, 2026 Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action” GlobeNewswire · Jun 18, 2026 Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water GlobeNewswire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-3.0M$1.0M$0$2.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-1.0M$-3.0M$1.0M$-1.0M$2.0M
Free Cash Flow$-1.0M$-3.0M$1.0M$-1.0M$2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.99
EV / EBITDA19.82
FCF Yield-1.66%
Quick Ratio2.71
Interest Coverage1642.00
Return 1Y3.68%
Return 3Y161.43%
Return 5Y-59.24%

Ownership

Insiders Held12.87%
Institutions Held49.09%
Institutions Float Held56.34%
Institutional HolderSharesReport Date
Wexford Capital LP3,600,5522026-03-31
Topline Capital Management, LLC581,9672026-03-31
Vanguard Capital Management LLC198,6432026-03-31
Cornerstone Capital, Inc.128,7002026-03-31
Bard Associates Inc.121,2022026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Nephros, Inc.

Nephros, Inc. is led by CEO Robert Banks, employs 31 people, headquartered in US, publicly traded since 2004.

Nephros, Inc. (NEPH) stock trades at $3.53 with a market capitalization of $38.32M. The stock is valued at a price-to-earnings (P/E) ratio of 22.84, price-to-book of 3.33, price-to-sales of 1.92. Over the past 52 weeks the stock has ranged between $2.66 and $6.42, and currently trades 45.0% below its 52-week high.

On profitability, Nephros, Inc. generates a return on equity (ROE) of 16.20%, above the typical market average, return on capital employed of 13.21%, an operating margin of 5.26%, a net profit margin of 8.38%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides